Abstract
A key feature of the clinical course of chronic lymphocytic leukemia (CLL) is that it induces a state of immunosuppression, causing increased susceptibility to infections and failure of anti-tumor immune responses. Cytotoxic chemotherapy still forms the mainstay of most current treatment regimens, but is not curative, and its lack of specificity means that it also targets normal immune cells, exacerbating this immunosuppression. This can result in effective treatments being limited by infectious complications, particularly in the elderly who comprise the majority of patients with this disease. Immunotherapy potentially offers a way out of this dilemma, due to its improved specificity and ability to enhance immune responses to both the tumor and infectious agents. There has been a dramatic increase in the range of available immunotherapeutic options over the past decade, and many are now in the process of making the transition to the clinic. This review will discuss both the immune defect in CLL, and emerging immunotherapies, including CD40 ligand gene therapy, lenalidomide, CLL vaccines, CXCR4 antagonists, and adoptive cellular immunotherapies such as chimeric antigen receptor modified T-cells.
Keywords: Chronic lymphocytic leukemia, immune suppression, T-cell, NK-cell, CXCR4, plerixafor, CAL-101, everolimus, PCI-32765, CD40 ligand, gene therapy, lenalidomide, cancer vaccine, allogeneic hemopoietic stem cell transplantation, chimeric antigen receptor
Current Pharmaceutical Design
Title:Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy
Volume: 18 Issue: 23
Author(s): John C. Riches, Alan G. Ramsay and John G. Gribben
Affiliation:
Keywords: Chronic lymphocytic leukemia, immune suppression, T-cell, NK-cell, CXCR4, plerixafor, CAL-101, everolimus, PCI-32765, CD40 ligand, gene therapy, lenalidomide, cancer vaccine, allogeneic hemopoietic stem cell transplantation, chimeric antigen receptor
Abstract: A key feature of the clinical course of chronic lymphocytic leukemia (CLL) is that it induces a state of immunosuppression, causing increased susceptibility to infections and failure of anti-tumor immune responses. Cytotoxic chemotherapy still forms the mainstay of most current treatment regimens, but is not curative, and its lack of specificity means that it also targets normal immune cells, exacerbating this immunosuppression. This can result in effective treatments being limited by infectious complications, particularly in the elderly who comprise the majority of patients with this disease. Immunotherapy potentially offers a way out of this dilemma, due to its improved specificity and ability to enhance immune responses to both the tumor and infectious agents. There has been a dramatic increase in the range of available immunotherapeutic options over the past decade, and many are now in the process of making the transition to the clinic. This review will discuss both the immune defect in CLL, and emerging immunotherapies, including CD40 ligand gene therapy, lenalidomide, CLL vaccines, CXCR4 antagonists, and adoptive cellular immunotherapies such as chimeric antigen receptor modified T-cells.
Export Options
About this article
Cite this article as:
C. Riches John, G. Ramsay Alan and G. Gribben John, Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy, Current Pharmaceutical Design 2012; 18 (23) . https://dx.doi.org/10.2174/138161212801227023
DOI https://dx.doi.org/10.2174/138161212801227023 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Late Life Depression: A Diagnostic and Pharmacological Review
Current Psychopharmacology Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology A Review on Skin Targeted Delivery of Bioactives as Ultradeformable Vesicles: Overcoming the Penetration Problem
Current Drug Targets Recent Patents on Nucleic Acid-Based Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
Current Cardiology Reviews Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use
Cardiovascular & Hematological Disorders-Drug Targets The Discovery and Development of Drug Combinations for the Treatment of Various Diseases from Patent Literature (1980-Present)
Current Topics in Medicinal Chemistry Cannabidiol Adverse Effects and Toxicity
Current Neuropharmacology Direct and Indirect Antimicrobial Activities of Neuropeptides and their Therapeutic Potential
Current Protein & Peptide Science Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics
Current Molecular Medicine Recent Applications of Nanomaterials Based on Electrochemical Drug Analysis
Current Analytical Chemistry Respiratory Failure in Cancer Patients: Non-Infectious Complications of Antineoplastic Agents for Solid Tumors
Current Respiratory Medicine Reviews Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Current Medicinal Chemistry Evidence that Cortical Dopamine is a Co-Transmitter in Noradrenergic Neurons
Current Psychiatry Reviews Vasopressin-Receptor Antagonists: A New Class of Agents for the Treatment of Hyponatremia
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
Current Hypertension Reviews